CFTR and cystic fibrosis: In a single dose, dose-escalation phase 1/2a safety trial assessment of a liposomal mixture that included the cationic lipid mixture (GL67A) complexed with CFTR complementary DNA, patients with CF showed improved lung function and no adverse effects (Alton et al., 2015b).